Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Amphastar Pharma (AMPH) Misses Q1 EPS by 3c
May 9, 2018 4:14 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of $0.05, $0.03 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $58.4 million versus the consensus estimate of $60.75 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More